Ongoing Clinical Trials for X-linked Lymphoproliferative Syndrome
Currently, there is one ongoing clinical trial focused on X-linked lymphoproliferative syndrome, specifically targeting patients with XIAP deficiency. This trial is investigating a treatment called Tadekinig alfa, which aims to reduce inflammation in patients with this rare genetic condition. The study is being conducted in Germany and focuses on the long-term safety of this investigational medication.
Clinical trial locations
Study on Tadekinig Alfa for Patients with NLRC4 Mutation and XIAP Deficiency
This clinical trial is examining the long-term safety and tolerability of Tadekinig alfa in patients with two rare genetic conditions: NLRC4 mutation and XIAP deficiency. XIAP deficiency is a form of X-linked lymphoproliferative syndrome that affects the immune system’s ability to control inflammation and cell death. Both conditions cause the immune system to become overactive, leading to chronic inflammation throughout the body.
Main inclusion criteria:
- Patients must have participated in a previous clinical trial for these conditions
- Patients should have completed at least the first 18-week phase of the previous study
- The gap between finishing the previous trial and starting this study should not exceed 3 months
- Women of childbearing potential must have a negative pregnancy test at all visits and agree to use highly effective birth control methods during the study and for one month after treatment ends
- Patients who stopped the previous trial due to treatment failure must wait at least 4 weeks before joining this study
Main exclusion criteria:
- Patients who have not participated in the previous clinical trial related to NLRC4 or XIAP conditions
- Patients who do not have the specific genetic mutations being studied
- Patients who are pregnant or breastfeeding
- Patients who have other medical conditions that might interfere with the study
- Patients who are unable to follow the study procedures or attend required follow-up visits
- Patients currently participating in another clinical trial that might affect the results
Focus and goal of the trial: This is an open-label extension study, meaning all participants receive the actual medication rather than a placebo. The main goal is to monitor how safe and well-tolerated Tadekinig alfa is when used over a longer period. The study will carefully track any side effects or adverse reactions that patients experience. Participants receive regular injections under the skin and attend regular check-ups with healthcare professionals to assess their health and any changes in their condition. The study also monitors how well patients’ bodies process the medication and how the injection sites tolerate the treatment.
Investigational drug: The medication being tested is Tadekinig alfa, also known by its code name rhIL-18BP. This medication is given as a solution injected under the skin. It works by blocking a protein called IL-18, which plays a key role in causing inflammation in the body. By reducing the activity of this protein, Tadekinig alfa aims to decrease inflammation and improve symptoms such as fever, rash, and joint pain. The medication is classified as an interleukin inhibitor, a type of drug that targets specific proteins involved in the immune response.
Summary
Currently, there is one ongoing clinical trial available for patients with X-linked lymphoproliferative syndrome, specifically those with XIAP deficiency. This trial is being conducted in Germany and represents a continuation of earlier research, as it requires participants to have already taken part in a previous study. The focus on Tadekinig alfa as an investigational treatment reflects ongoing efforts to find effective therapies for these rare autoinflammatory conditions. The trial emphasizes long-term safety monitoring, which is important for understanding how this medication performs over extended periods of use. Patients interested in participating should note that this is a specialized study with specific eligibility requirements related to previous trial participation.
